slotkoers
Andere beurzen
|
||
- USD | - |
06:31 | Beursagenda: buitenlandse fondsen | AM |
05:55 | Genmab, Pfizer krijgen goedkeuring van Amerikaanse FDA voor behandeling tegen baarmoederhalskanker | MT |
Omzet 2024 * | 59,96 mld. 55,93 mld. | Omzet 2025 * | 62,57 mld. 58,37 mld. | Marktkapitalisatie | 145 mld. 135 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 6,75 mld. 6,29 mld. | Nettowinst (verlies) 2025 * | 9,29 mld. 8,67 mld. | EV/omzet 2024 * | 3,21 x |
Nettoschuld 2024 * | 47,04 mld. 43,88 mld. | Nettoschuld 2025 * | 41,91 mld. 39,1 mld. | EV/omzet 2025 * | 2,99 x |
K/w-verhouding 2024 * |
18,8
x | K/w-verhouding 2025 * |
13,7
x | Werknemers | - |
Dividendrendement 2024 * |
6,61% | Dividendrendement 2025 * |
6,78% | Vrij verhandelbaar | 59,09% |
Recentste transcriptie over Pfizer Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 01-01-93 |
David Denton
DFI | Director of Finance/CFO | 59 | 02-05-22 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 66 | 01-04-20 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 23-02-17 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 27-09-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,47% | 664 mld. | |
+29,78% | 567 mld. | |
-6,33% | 354 mld. | |
+19,35% | 330 mld. | |
+4,23% | 286 mld. | |
+14,27% | 234 mld. | |
+5,01% | 199 mld. | |
-10,02% | 196 mld. | |
-4,04% | 148 mld. |